Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: Results of the phase II GINECO trial CAPYTTOLE

Annals of Oncology

Volumn 20, Issue 12, 2009, Pages 1959-1963

  de la Fouchardiere C ^a   Largillier, R ^b   Goubely, Y ^c   Hardy Bessard, A C ^d   Slama, B ^e   Cretin, J ^f   Orfeuvre, H ^g   Paraiso, D ^h   Bachelot, T ^a   Pujade Lauraine, E ^i,j  

^a CENTRE LÉON BÉRARD   (France)

^b Centre Azuréen Cancérologie   (France)

^c INSTITUT SAINTE CATHERINE   (France)

^d Clinique Armoricaine de Radiologie   (France)

^e CENTRE HOSPITALIER D AVIGNON   (France)

^f Clinique Bonnefon   (France)

^g Hopital Fleyriat   (France)

^h Centre Hospitalier de l'Agglomeration Montargeoise   (France)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j HÔTEL DIEU   (France)

more..

Author keywords

Docetaxel; First line chemotherapy; Metastatic breast cancer; Pegylated liposomal doxorubicin

Indexed keywords

DOCETAXEL; DOXORUBICIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; VISCERAL METASTASIS;

EID: 70849107684     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp231     Document Type: Article

References (17)

1. Singletary SE, Connolly JL. Breast cancer staging: Working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006; 56: 37-47.
2. Fossati R, Confalonieri C, Torri V et al. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16: 3439-3460.
3. Carrick S, Parker S, Wilcken N et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005; (2): CD003372.
4. A'Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993; 67: 801-805.
5. Crown J, Dieras V, Kaufmann M et al. Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol 2002; 3: 719-727.
6. Martin FJ. Pegylated liposomal doxorubicin: Scientific rationale and preclinical pharmacology. Oncology 1997; 11 (Suppl 11): 11-20.
7. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-449.
8. Guastalla JP, Hardy-Bessard AC, Geay JF et al. Phase I study of pegylated liposomal doxorubicin (CA) and docetaxel (T) bimonthly in the first-line treatment of metastatic breast cancer (MBC): The CAT regimen. Proc Am Soc Clin Oncol 2004; 22: (Abstr 818).
9. Alexopoulos A, Karamouzis MV, Stavrinides H et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 2004; 15: 891-895.
10. Sparano JA, Malik U, Rajdev L et al. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 2001; 19: 3117-3125.
11. Morabito A, Gattuso D, Stani SC et al. Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer. Breast Cancer Res Treat 2004; 86: 249-257.
12. Nabholtz JM, Falkson C, Campos D et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21: 968-975.
13. Mackey JR, Paterson A, Dirix LY et al. Final results of the phase III randomized trial comparing docetaxel, doxorubicin and cyclophosphamide to FAC as first line chemotherapy for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21: (Abstr 137).
14. Bontenbal M, Creemers GJ, Braun HJ et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005; 23: 7081-7088.
15. Briasoulis E, Karavasilis V, Tzamakou E et al. Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol 2004; 53: 452-457.
16. D'Incalci M, Schuller J, Colombo T et al. Taxoids in combination with anthracyclines and other agents: Pharmacokinetic considerations. Semin Oncol 1998; 25 (Suppl 13): S16-S20.
17. Gennari A, Conte P, Nanni O et al. Multicenter randomised trial of paclitaxel (P) maintenance chemotherapy (CT) versus control in metastatic breast cancer (MBC) patients achieving a response or stable disease to first-line CT including anthracyclines and paclitaxel: Final results from the Italian MANTA study. Proc Am Soc Clin Oncol 2005; 23: (Abstr 522).